Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ratios of granulocyte macrophage colony-stimulating factor and interleukin 1β cytokines, produced in tumor, to the expression of CSF2RA and IL1R2 depend on levels of interleukin 6, interleukin 8, tumor necrosis factor α, interferon γ, granulocyte colony-stimulating factor, and vascular endothelial growth factor A and are important factors affecting the progression and metastasis of the breast cancer.
|
31635541 |
2020 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, vascular endothelial growth factor (VEGF) was used to induce endothelial differentiation of breast cancer stem‑like cells (BCSLCs), and methods including flow cytometry, western blotting and immunofluorescence were used to study the relationship between autophagy and the endothelial differentiation of BCSLCs.
|
31746369 |
2020 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the current study was to assess the effect of coenzyme Q10 supplementation on serum levels of interleukin 6, 8, and vascular endothelial growth factor (VEGF) in patients with breast cancer undergoing tamoxifen therapy by a double-blind, placebo-controlled, randomized clinical trial.
|
31824163 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation.
|
31228519 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results highlight that the survival of breast cancer patients with high co-expression of VEGF and IL-6 family cytokines is dependent on breast cancer subtype.
|
30439625 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer.
|
30939479 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HMGB1 enhanced vessel formation in breast cancer tissues by regulating hypoxia-inducible factor 1 (HIF-1alpha), which in turn upregulates the expression of VEGF.
|
30930461 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together our findings suggested that SAL inhibits VEGF induced angiogenesis and breast cancer growth via interrupting HIF-1α/VEGF signalling and could be used as a promising antiangiogenic agent for breast cancer treatment.
|
31028743 |
2019 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A significantly higher concentration of the soluble form of VEGF receptor type 1 in patients with T1 breast cancer in relation to T2 cases was noted.
|
30818220 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, F3 significantly reduced the expression of MMP-9, MUC1, N-cadherin, Twist, VEGF and vimentin in comparison with the TM (p < 0.01) group CONCLUSIONS: Our findings suggest that F3 exerts anti-metastatic effects independent of its cytotoxic effects, and these are supported by the increased expression of E-cadherin concurrent with downregulation of MMP-9, MUC1, N-cadherin, Twist, VEGF and vimentin expression in breast cancer.
|
30594607 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings indicate that downregulation of miR20b by ASCs/SCF activates HIF-1α/VEGFA and induces BC cell EMT and metastasis, suggesting that this process is activated by the p-c-Kit/MAPK-p38/E2F1 pathway.
|
31254605 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of breast cancer cell line derived VEGF by TCH-5c was shown through ELISA and the use of conditioned media.
|
30947677 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pro-angiogenic factors, including vascular endothelial growth factor (VEGF), have been recognized as pivotal therapeutic targets in the treatment of breast cancer.
|
30788837 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACE2 downregulated the expression of VEGFa in breast cancer cells.
|
31023337 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correction: FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
|
30867566 |
2019 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A further finding in the TCGA database shows that breast cancer patients with ≥2 mutated genes in VEGF pathways showed worse prognosis (p = 0.0013).
|
30888194 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Level 1: The use of afatinib is not recommended in patients with brain metastasis due to breast cancer.There is insufficient evidence to make recommendations regarding: the use of epidermal growth factor receptor inhibitors erlotinib and gefitinib in patients with brain metastasis due to nonsmall cell lung cancerthe use of BRAF inhibitors dabrafenib and vemurafenib in the treatment of patients with brain metastases due to metastatic melanomathe use of HER2 agents trastuzumab and lapatinib to treat patients with brain metastases due to metastatic breast cancerthe use of vascular endothelial growth factor agents bevacizumab, sunitinib, and sorafenib in the treatment of patients with solid tumor brain metastases.The full guideline can be found at: https://www.cns.org/guidelines/guidelines-treatment-adults-metastatic-brain-tumors/chapter_9.
|
30629215 |
2019 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, the expression of ISL1 was also associated with the expression of vascular endothelial growth factor (VEGF) in breast cancer, and ISL1 promoted angiogenesis in breast cancer.
|
29497310 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of miR-20b and VEGF on breast cancer cells were also assessed after transfections.
|
28550685 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study.
|
29705024 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the extracellular <i>in vivo</i> levels of IL-8 were 40-fold higher than those of VEGF in human BC.
|
30105032 |
2018 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear FOXP3 expression was inversely correlated with VEGF expression in clinical breast cancer tissues, and FOXP3 downregulation and VEGF upregulation were both correlated with reduced survival in breast cancer data sets in the Kaplan-Meier plotter.
|
29970908 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This finding supports the biological role of VEGF in breast cancer.
|
30003393 |
2018 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ANG-1, ANG-2 and VEGF levels in co-culture media and mRNA expression were upregulated and Tie2 mRNA expression was downregulated in the HUVECs and MCF-7.
|
29115538 |
2018 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since TQ has been reported to up-regulate several growth factors such as vascular endothelial growth factor (VEGF), EGF and PTEN expression, the present review article discusses the targeting potential of TQ for therapeutic intervention against such types of breast cancer.
|
28606050 |
2018 |